Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)

다국어 초록 (Multilingual Abstract)

The epithelial-mesenchymal transition (EMT)comprises an essential biological process involving cancer progression as well as initiation. While the EMT has been regarded as a phenotypic conversion from epithelial to mesenchymal cells, recent evidence indicates that it plays a critical role in stemness, metabolic reprogramming, immune evasion and therapeutic resistance of cancer cells. Interestingly, several transcriptional repressors including Snail (SNAI1), Slug (SNAI2) and the ZEB family constitute key players for EMT in cancer as well as in the developmental process. Note that the dynamic conversion between EMT and epithelial reversion (mesenchymal-epithelial transition, MET) occurs through variable intermediate-hybrid states rather than being a binary process. Given the close connection between oncogenic signaling and EMT repressors, the EMT has emerged as a therapeutic target or goal (in terms of MET reversion) in cancer therapy. Here we review the critical role of EMT in therapeutic resistance and the importance of EMT as a therapeutic target for human cancer.

참고문헌 (Reference)

1 Kim T, "p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2" 208 : 875-883, 2011

2 Kim NH, "p53 and microRNA-34 are suppressors of canonical Wnt signaling" 4 : 71-, 2011

3 Siemens H, "miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions" 10 : 4256-4271, 2011

4 Fodde R, "Wnt/beta-catenin signaling in cancer stemness and malignant behavior" 19 : 150-158, 2007

5 Yook JI, "Wnt-dependent regulation of the E-cadherin repressor snail" 280 : 11740-11748, 2005

6 Basset-Seguin N, "Vismodegib in patients with advanced basal cell carcinoma(STEVIE) : a preplanned interim analysis of an international, open-label trial" 16 : 729-736, 2015

7 Thornton K, "Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease : U. S. Food and Drug Administration drug approval summary" 18 : 3722-3730, 2012

8 Chau NG, "Vandetanib for the treatment of medullary thyroid cancer" 19 : 524-529, 2013

9 Bennasroune A, "Tyrosine kinase receptors as attractive targets of cancer therapy" 50 : 23-38, 2004

10 Figueroa-Magalhaes MC, "Treatment of HER2-positive breast cancer" 23 : 128-136, 2014

11 Polyak K, "Transitions between epithelial and mesenchymal states : acquisition of malignant and stem cell traits" 9 : 265-273, 2009

12 Savagner P, "The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition" 137 : 1403-1419, 1997

13 Spaderna S, "The transcriptional repressor ZEB1promotes metastasis and loss of cell polarity in cancer" 68 : 537-544, 2008

14 Moody SE, "The transcriptional repressor Snail promotes mammary tumor recurrence" 8 : 197-209, 2005

15 Batlle E, "The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells" 2 : 84-89, 2000

16 Cano A, "The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression" 2 : 76-83, 2000

17 Aigner K, "The transcription factor ZEB1(deltaEF1)promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity" 26 : 6979-6988, 2007

18 Vandewalle C, "The role of the ZEB family of transcription factors in development and disease" 66 : 773-787, 2009

19 Wang Z, "The role of Notch signaling pathway in epithelial-mesenchymal transition(EMT)during development and tumor aggressiveness" 11 : 745-751, 2010

20 Gregory PA, "The miR-200family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1" 10 : 593-601, 2008

21 Korpal M, "The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2" 283 : 14910-14914, 2008

22 Briscoe J, "The mechanisms of Hedgehog signalling and its roles in development and disease" 14 : 416-429, 2013

23 White PT, "The discovery and development of sorafenib for the treatment of thyroid cancer" 10 : 427-439, 2015

24 Hajra KM, "The SLUG zinc-finger protein represses E-cadherin in breast cancer" 62 : 1613-1618, 2002

25 Tauriello DVF, "TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis" 554 : 538-543, 2018

26 Mariathasan S, "TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells" 554 : 544-554, 2018

27 Lamouille S, "TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion" 125 : 1259-1273, 2012

28 Akhurst RJ, "TGF-beta signaling in cancer—a double-edged sword" 11 : S44-S51, 2001

29 Katsuno Y, "TGF-beta signaling and epithelial-mesenchymal transition in cancer progression" 25 : 76-84, 2013

30 Bhola NE, "TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer" 123 : 1348-1358, 2013

31 Valcourt U, "TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition" 16 : 1987-2002, 2005

32 Franci C, "Snail1 protein in the stroma as a new putative prognosis marker for colon tumours" 4 : e5595-, 2009

33 Li X, "Snail induction is an early response to Gli1that determines the efficiency of epithelial transformation" 25 : 609-621, 2006

34 Come C, "Snail and slug play distinct roles during breast carcinoma progression" 12 : 5395-5402, 2006

35 Fendrich V, "Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum" 14 : 865-874, 2007

36 Zhang X, "Snail and Axin2 expression predict the malignant transformation of oral leukoplakia" 73 : 48-55, 2017

37 Chang TH, "Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor" 183 : 1071-1079, 2011

38 Derynck R, "Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition" 31 : 56-66, 2014

39 Gonzalez DM, "Signaling mechanisms of the epithelial-mesenchymal transition" 7 : re8-, 2014

40 Spigel DR, "Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-smallcell lung cancer : METLung" 35 : 412-420, 2017

41 Witta SE, "Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines" 66 : 944-950, 2006

42 Craene BD, "Regulatory networks defining EMT during cancer initiation and progression" 13 : 97-, 2013

43 Hsu DS, "Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer" 16 : 4561-4571, 2010

44 Rizzo P, "Rational targeting of Notch signaling in cancer" 27 : 5124-5131, 2008

45 Spigel DR, "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer" 31 : 4105-4114, 2013

46 Yoshida T, "RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation" 90 : 477-483, 2015

47 Hoffman LM, "Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies : a pediatric brain tumor consortium study" 31 : 1283-1289, 2015

48 Simonelli M, "Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma" 27 : 1782-1787, 2016

49 Morris JC, "Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma" 9 : e90353-, 2014

50 Krop I, "Phase I pharmacologic and pharmacodynamic study of the gamma secretase(Notch)inhibitor MK-0752 in adult patients with advanced solid tumors" 30 : 2307-2313, 2012

51 Lee SM, "Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma : SWOG 0933" 121 : 432-440, 2015

52 Ikeda M, "Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer" 79 : 1169-1177, 2017

53 Mayo C, "Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications" 13 : 789-802, 2012

54 Tuhkanen H, "Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression" 9 : 289-, 2009

55 Sahlgren C, "Notch signaling mediates hypoxia-induced tumor cell migration and invasion" 105 : 6392-6397, 2008

56 Caglevic C, "Nintedanib in non-small cell lung cancer : from preclinical to approval" 9 : 164-172, 2015

57 Ahn SY, "Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting axin-GSK3 interaction" 8 : 31842-31855, 2017

58 Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)" 45 : 228-247, 2009

59 Kang JS, "New regulatory mechanisms of TGF-beta receptor function" 19 : 385-394, 2009

60 Lustig B, "Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors" 22 : 1184-1193, 2002

61 Lamouille S, "Molecular mechanisms of epithelial-mesenchymal transition" 15 : 178-196, 2014

62 Chaffer CL, "Mesenchymal to epithelial transition in development and disease" 185 : 7-19, 2007

63 Graham TR, "Insulinlike growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells" 68 : 2479-2488, 2008

64 Arend RC, "Inhibition of Wnt/beta-catenin pathway by niclosamide : a therapeutic target for ovarian cancer" 134 : 112-120, 2014

65 Anderton MJ, "Induction of heart valve lesions by small-molecule ALK5 inhibitors" 39 : 916-924, 2011

66 Zoli W, "In vitro preclinical models for a rational design of chemotherapy combinations in human tumors" 37 : 69-82, 2001

67 Fan W, "In vitro evaluation of combination chemotherapy against human tumor cells(Review)" 5 : 1035-1042, 1998

68 Chockley PJ, "Immunological consequences of epithelial-mesenchymal transition in tumor progression" 197 : 691-698, 2016

69 Gupta PB, "Identification of selective inhibitors of cancer stem cells by high-throughput screening" 138 : 645-659, 2009

70 Yang Q, "Idelalisib : first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma" 21 : 1537-1542, 2015

71 Grotegut S, "Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail" 25 : 3534-3545, 2006

72 Moreno-Bueno G, "Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition" 66 : 9543-9556, 2006

73 Rodon J, "First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma" 21 : 553-560, 2015

74 Lang L, "FDA approves sorafenib for patients with inoperable liver cancer" 134 : 379-, 2008

75 Vogelzang NJ, "Everolimus vs. temsirolimus for advanced renal cell carcinoma : use and use of resources in the US Oncology Network" 11 : 115-120, 2013

76 Murphy M, "Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer : a systematic review" 14 : 177-190, 2011

77 Marcucci F, "Epithelial–mesenchymal transition : a new target in anticancer drug discovery" 15 : 311-, 2016

78 Thiery JP, "Epithelialmesenchymal transitions in development and disease" 139 : 871-890, 2009

79 Thiery JP, "Epithelial-mesenchymal transitions in tumour progression" 2 : 442-454, 2002

80 Kalluri R, "Epithelial-mesenchymal transition and its implications for fibrosis" 112 : 1776-1784, 2003

81 Arumugam T, "Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer" 69 : 5820-5828, 2009

82 Kuczynski EA, "Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma" 75 : 2510-2519, 2015

83 Shah MA, "Effect of Fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma : the METGastric randomized clinical trial" 3 : 620-627, 2017

84 Park CY, "EW-7203, a novel small molecule inhibitor of transforming growth factor-beta(TGFbeta)type I receptor/activin receptor-like kinase-5, blocks TGFbeta1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells" 102 : 1889-1896, 2011

85 Son JY, "EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis" 13 : 1704-1716, 2014

86 Sanchez-Tillo E, "EMTactivating transcription factors in cancer : beyond EMT and tumor invasiveness" 69 : 3429-3456, 2012

87 Nieto MA, "EMT: 2016" 166 : 21-45, 2016

88 Haslehurst AM, "EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer" 12 : 91-, 2012

89 Tryndyak VP, "E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells" 126 : 2575-2583, 2010

90 Lu Z, "Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion" 4 : 499-515, 2003

91 Kroepil F, "Downregulation of CDH1 is associated with expression of SNAI1 in colorectal adenomas" 7 : e46665-, 2012

92 Irie HY, "Distinct roles of Akt1and Akt2 in regulating cell migration and epithelial-mesenchymal transition" 171 : 1023-1034, 2005

93 Wilhelm S, "Discovery and development of sorafenib : a multikinase inhibitor for treating cancer" 5 : 835-844, 2006

94 Lacouture ME, "Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab(GC1008)" 64 : 437-446, 2015

95 Kim HJ, "Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail" 27 : 3165-3175, 2007

96 Imai K, "Comparing antibody and small-molecule therapies for cancer" 6 : 714-727, 2006

97 Zhang W, "Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7human breast cancer cells" 417 : 679-685, 2012

98 Lamouille S, "Cell size and invasion in TGF-betainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway" 178 : 437-451, 2007

99 Wu ZQ, "Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic breast cancer 1, early onset(BRCA1)repression" 109 : 16654-16659, 2012

100 Zhu Y, "Biological and clinical significance of cancer stem cell plasticity" 3 : 32-, 2014

101 Wieland A, "Anticancer effects of niclosamide in human glioblastoma" 19 : 4124-4136, 2013

102 Bezdekova M, "Analysis of Snail-1, E-cadherin and claudin-1expression in colorectal adenomas and carcinomas" 13 : 1632-1643, 2012

103 Hay ED, "An overview of epithelio-mesenchymal transformation" 154 : 8-20, 1995

104 Park CY, "An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition" 351 : 72-80, 2014

105 Xie L, "Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro" 6 : 603-610, 2004

106 Pattabiraman DR, "Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumorinitiating ability" 351 : aad3680-, 2016

107 Yochum GS, "AXIN2: tumor suppressor, oncogene or both in colorectal cancer?" 4 : 7-8, 2012

108 Spaderna S, "A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer" 131 : 830-840, 2006

109 De Jesus-Acosta A, "A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma" 32 : 739-745, 2014

110 Diaz-Padilla I, "A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinumresistant epithelial ovarian cancer : a study of the Princess Margaret, Chicago and California phase II consortia" 137 : 216-222, 2015

111 Strosberg JR, "A phase II study of RO4929097 in metastatic colorectal cancer" 48 : 997-1003, 2012

112 Wheatley-Price P, "A phase II study of PF-03446962 in patients with advanced malignant pleural mesothelioma. CCTG Trial IND. 207" 11 : 2018-2021, 2016

113 Brandes AA, "A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma" 18 : 1146-1156, 2016

114 Goff LW, "A phase I study of the anti-activin receptor-like kinase 1(ALK-1)monoclonal antibody PF-03446962 in patients with advanced solid tumors" 22 : 2146-2154, 2016

115 Bracken CP, "A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition" 68 : 7846-7854, 2008

116 Yook JI, "A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells" 8 : 1398-1406, 2006

117 Vincent T, "A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition" 11 : 943-950, 2009